Lonnel Coats, Lexicon Pharmaceuticals CEO
July 13, 2022 01:14 PM EDTUpdated 03:57 PM
FDA+

FDA again spells out safe­ty con­cerns with oral type 1 di­a­betes drug while deny­ing Lex­i­con's at­tempt to over­turn a CRL

Zachary Brennan

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

HHS says it's pulled Covid shot guid­ance for healthy kids. The CDC vac­cine sched­ule shows oth­er­wise

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

Lil­ly to buy non-opi­oid pain biotech SiteOne for up to $1B

Ver­tex touts promis­ing first few months of launch for non-opi­oid pain drug Jour­navx

Ver­tex's next chal­lenge for pain pill? Crack­ing a mar­ket dom­i­nat­ed by cheap opi­oids

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times